KLK3 and prostate cancer: Patients with a 1-PSA between 4.0 and 10.0 ng/mL had a significantly lower risk of developing prostate cancer in the decrease group than in the reference group (adjusted HR = 0.27, 95% CI = 0.10–0.76).